Handelsavisen
prelaunch
Companies Healthcare 2633.HK
26
2633.HK HKEX Pharmaceuticals

2633.Hk

HK$1,10
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,2B HKD
P/E
EV / Rev
Div yield
8,63 %
Op margin
26,3 %
ROE
12,3 %
Net margin
19,1 %
Debt / equity
0,32
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products, primarily in the healthcare sector.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products, primarily in the healthcare sector.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target2,45

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
2,45
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
1 analysts · indicative
Ownership
not yet wired
Profitability
12,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2633.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2633.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products, primarily in the healthcare sector.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company maintains a conservative capital structure, with a debt-to-equity ratio of 0.32, indicating a relatively low reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 1.88, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow of 136.75 million HKD is significantly lower than its operating cash flow of 526.78 million HKD, indicating that capital expenditures are consuming a large portion of its operating cash flow.

    In terms of profitability, the company's return on equity (ROE) of 12.26% and return on assets (ROA) of 8.25% are strong indicators of efficient use of equity and assets. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key performance indicators. The company's gross profit margin of 43.93% and operating margin of 26.30% also suggest a healthy profitability profile, although a direct comparison to industry medians is not available in the provided data.

    The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. This lack of diversification may pose a concentration risk, as the company's performance is heavily dependent on the success of its primary business segment. The absence of geographic data limits the ability to assess regional exposure and potential diversification benefits.

    The company's growth trajectory is positive, with a current revenue of 1.58 billion HKD. While specific growth rates are not provided, the company's operating income of 414.60 million HKD and net income of 300.83 million HKD indicate a stable and profitable operation. Analysts have set a mean price target of 2.45 HKD, which is significantly higher than the current market price of 1.16 HKD, suggesting a potential for upward movement in the stock price.

    The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates a potential liquidity constraint. However, the company's low dilution risk suggests that there is minimal threat from share issuance that could dilute existing shareholders' equity. The absence of recent dilutive events and the low dilution potential further support this assessment.

    Recent events and disclosures do not provide specific details on recent filings or transcripts. However, the company's financial performance and analyst estimates suggest a positive outlook. The mean recommendation of 1.00 (strong buy) from analysts indicates strong confidence in the company's future performance. The absence of recent negative events and the positive analyst sentiment contribute to a favorable investment outlook.

    Key takeaways
    • The company has a strong return on equity (12.26%) and return on assets (8.25%), indicating efficient use of capital.
    • The company's liquidity position is medium, with a current ratio of 1.88, suggesting adequate short-term financial health.
    • The company's free cash flow is significantly lower than its operating cash flow, indicating high capital expenditures.
    • Analysts have set a mean price target of 2.45 HKD, which is significantly higher than the current market price of 1.16 HKD.
    • The company's risk profile is characterized by medium liquidity risk and low dilution risk.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    HK$1,10
    Market cap
    HK$2.32B
    Enterprise value
    HK$3.09B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    5.9x
    P / B
    0.9x
    P / Tangible book
    0.9x
    Tangible book
    HK$2.45B
    Net cash
    -HK$773.2M
    Current ratio
    1.9
    Debt / equity
    0.3
    ROA
    8.2%
    ROE
    12.3%
    Cash conversion
    175.0%
    CapEx / revenue
    -15.8%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price targetHK$2,45 · Median HK$2,45
    Low HK$2,45High HK$2,45
    Operating income · consensus342,1M HKD

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$2,45
    MeanHK$2,45
    MedianHK$2,45
    HighHK$2,45
    SpotHK$1,10
    +122.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin26,3 %Above P75
    Net Margin19,1 %Above P75
    ROE12,3 %Above P75
    Capex / Rev-15,8 %Bottom quartile
    D/E0,32Below median
    Cash Conv1,75Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • 2633.HK Market data — financials · 2026-05-26
    • Jacobson Pharma Corporation Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2633.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage